These findings support the view that, in patients with EGFR-TKI-resistant non-small cell lung cancer, ACTL can deliver meaningful clinical benefit with manageable toxicity and warrants broader evaluation in multicenter settings. Here, EGFR is linked to non-small cell lung carcinoma.